Welcome to China SXT Pharmaceuticals, Inc. Official Website!
Hotline:
+86-523-86299087
Email:
ir@sxtchina.com
NASDAQ:
SXTC
Contact Us
Toggle navigation
HOME
ABOUT
COMPANY
TEAM
COMPANY STRUCTURE
COMPANY AWARDS
CONTACT
BRAND
BRAND HISTORY
R&D
RESEARCH AND DEVELOPMENT
R&D STRATEGY
INTELLECTUAL PROPERTY RIGHT
MEDIA
LATEST NEWS
COMPANY NEWS
INVESTORS
STOCK INFO
SEC FILINGS
FINANCIALS
PRESS
SHAREHOLDER SERVICES
PUBLIC POLICIES
POLICIES
GUIDELINES
X
HOME
ABOUT
COMPANY
TEAM
COMPANY STRUCTURE
COMPANY AWARDS
CONTACT
BRAND
BRAND HISTORY
R&D TEAM
RESEARCH AND DEVELOPMENT
R&D STRATEGY
INTELLECTUAL PROPERTY RIGHT
PRODUCT
DIRECTLY-ORAL TCMP
AFTER-SOAKING-ORAL TCMP
FINE TCMP
REGULAR TCMP
MEDIA
LATEST NEWS
COMPANY NES
INVESTORS
STOCK INFO
SEC FILINGS
FINANCIALS
PRESS
SHAREHOLDER SERVICES
PUBLIC POLICIES
POLICIES
GUIDELINES
NASDAQ NEWS
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
Release：sxtchina Browse：2623次
Last：
China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory
Next：
China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques
Sweep open